Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05564377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05564377 · ClinicalTrials.gov record · last posted 2026-08-19

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

StatusRecruiting
PhasePhase 2
Started2023-04-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Protocol amendment history 1 change detected by DataLookout

2026-04-07
minor
Trial sites expanded: 477 → 480 locations
Trial Details
NCT Number NCT05564377
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma +7 more
Enrollment 2,900 participants
Start Date 2023-04-07
Primary Completion 2030-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-19